Subsidiaries of Astellas and Novartis co-led a round featuring GV and 6 Dimensions Capital that took the cancer drug developer's overall funding to $60m.

US-based oncology therapy developer TScan Therapeutics has closed a $35m series B round that included vehicles for pharmaceutical firms Astellas and Novartis. Novartis Institutes for BioMedical Research and Astellas Venture Management co-led the round with venture capital fund Pitango Venture Capital, while Novartis also invested through its Novartis Venture Fund. Internet and technology group Alphabet…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.